Journal article · 2023 · Open access

Using Risk of Bias 2 to assess results from randomised controlled trials: guidance from Cochrane

Ella Flemyng, Theresa HM Moore, Isabelle Boutron, Julian P. T. Higgins, Asbjørn Hróbjartsson, Camilla Hansen Nejstgaard, Kerry M. Dwan

BMJ Evidence-Based Medicine, 28(4), 260–266 · Published 24 January 2023 · DOI 10.1136/bmjebm-2022-112102

Free PDFView at the publisherCite this paper

In brief

“Using Risk of Bias 2 to assess results from randomised controlled trials: guidance from Cochrane” is a 2023 journal article by Ella Flemyng and 6 co-authors, published in BMJ Evidence-Based Medicine. OpenAlex counts 309 citations as of 15 November 2026, which puts it in the top 1% of works published in 2023 by citations. It is open access: the full text is free to read at BMJ Evidence-Based Medicine.

Citations
309
Most cited in
2026 (135)
Field-weighted impact
29.98
References
17
Authors
7

Abstract

A systematic review identifies, appraises and synthesises all the empirical evidence from studies that meet prespecified eligibility criteria to answer a specific research question. As part of the appraisal, researchers use explicit methods to assess risk of bias in the results' from included studies that contribute to the review's findings, to improve our confidence in the review's conclusions. Randomised controlled trials included in Cochrane Reviews have used a specific risk of bias tool to assess these included studies since 2008. In 2019, a new version of this tool, Risk of Bias 2 (RoB 2), was launched to improve its usability and to reflect current understanding of how the causes of bias can influence study results. Cochrane implemented RoB 2 in a phased approach, with users of the tool informing guidance development. This paper highlights learning for all systematic reviewers (Cochrane and non-Cochrane) from the phased implementation, highlighting differences between the original version of the tool and RoB 2, consideration of reporting systematic review protocols or full review reports that have used RoB 2, and some tips shared by authors during the pilot phase of the implementation.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Flemyng, E., Moore, T. H., Boutron, I., Higgins, J. P. T., Hróbjartsson, A., Nejstgaard, C. H., & Dwan, K. M. (2023). Using Risk of Bias 2 to assess results from randomised controlled trials: guidance from Cochrane. BMJ Evidence-Based Medicine, 28(4), 260–266. https://doi.org/10.1136/bmjebm-2022-112102

MLA 9

Flemyng, Ella, et al. “Using Risk of Bias 2 to assess results from randomised controlled trials: guidance from Cochrane.” BMJ Evidence-Based Medicine, vol. 28, no. 4, 2023, pp. 260–266. https://doi.org/10.1136/bmjebm-2022-112102.

Chicago

Flemyng, Ella, Theresa HM Moore, Isabelle Boutron, Julian P. T. Higgins, Asbjørn Hróbjartsson, Camilla Hansen Nejstgaard, and Kerry M. Dwan. 2023. “Using Risk of Bias 2 to assess results from randomised controlled trials: guidance from Cochrane.” BMJ Evidence-Based Medicine 28 (4): 260–266. https://doi.org/10.1136/bmjebm-2022-112102.

Harvard

Flemyng, E. et al. (2023) ‘Using Risk of Bias 2 to assess results from randomised controlled trials: guidance from Cochrane’, BMJ Evidence-Based Medicine, 28(4), pp. 260–266. doi:10.1136/bmjebm-2022-112102.

IEEE

E. Flemyng et al., “Using Risk of Bias 2 to assess results from randomised controlled trials: guidance from Cochrane,” BMJ Evidence-Based Medicine, vol. 28, no. 4, pp. 260–266, 2023, doi: 10.1136/bmjebm-2022-112102.

BibTeX

@article{flemyng2023using,
  title     = {{Using Risk of Bias 2 to assess results from randomised controlled trials: guidance from Cochrane}},
  author    = {Flemyng, Ella and Moore, Theresa HM and Boutron, Isabelle and Higgins, Julian P. T. and Hróbjartsson, Asbjørn and Nejstgaard, Camilla Hansen and Dwan, Kerry M.},
  journal   = {BMJ Evidence-Based Medicine},
  year      = {2023},
  volume    = {28},
  number    = {4},
  pages     = {260--266},
  doi       = {10.1136/bmjebm-2022-112102},
  url       = {https://doi.org/10.1136/bmjebm-2022-112102}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
20231717
20244343
2025114114
2026135135

Its field-weighted citation impact is 29.98: it has been cited 29.98 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews

  • risk of bias assessment
  • randomized controlled trials

Work with this paper

Most-cited papers in Decision Sciences

All highly cited Decision Sciences papers

Questions about this paper

How do I cite this paper in APA style?

Flemyng, E., Moore, T. H., Boutron, I., Higgins, J. P. T., Hróbjartsson, A., Nejstgaard, C. H., & Dwan, K. M. (2023). Using Risk of Bias 2 to assess results from randomised controlled trials: guidance from Cochrane. BMJ Evidence-Based Medicine, 28(4), 260–266. https://doi.org/10.1136/bmjebm-2022-112102

How many times has this paper been cited?

309 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access: read the free full text at BMJ Evidence-Based Medicine.

Who wrote this paper?

Ella Flemyng, Theresa HM Moore, Isabelle Boutron, Julian P. T. Higgins, Asbjørn Hróbjartsson, Camilla Hansen Nejstgaard, Kerry M. Dwan.

What is the DOI of this paper?

10.1136/bmjebm-2022-112102. The permanent link is https://doi.org/10.1136/bmjebm-2022-112102.

Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.